Pfizer Inc. (PFE)
Pfizer: It's Time To Play Defensive
Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely to be quite positive for Pfizer, as the optimism around growth stocks is fading. Patent cliff risks exist, but Pfizer's substantial R&D investments and solid fundamentals make it a compelling high-yield investment.
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year.
3 Ultra-Cheap Dividend Stocks to Buy Right Now
If you want to generate significant long-term gains in the stock market, one place to start looking for investments is among the companies that Wall Street isn't all that thrilled with today. In the short term, these may not be good performers, and they may not have looked like great buys in recent months or years.
1 Stock Down 43% That Looks Too Cheap to Ignore
Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently experiencing, it's possible to find attractive companies to invest in at attractive prices.
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Despite modest 2025 guidance, Pfizer's oncology and anti-obesity drugs present growth potential, countering analysts' low expectations. However, risks remain, which include political challenges and patent expirations.
Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
Pfizer's CEO said he may move manufacturing back to the US in response to Donald Trump's tariffs. Albert Bourla said he was not surprised by Trump's victory in November.
Pfizer Inc. (PFE) TD Cowen 45th Annual Health Care Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) TD Cowen 45th Annual Health Care Conference March 3, 2025 10:30 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again, and welcome to TD Cowen's 45th Annual Healthcare Conference. We are absolutely delighted to have Pfizer with us again this year.
Pfizer could move outside manufacturing to the US, says CEO
Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as President Donald Trump's administration threatens numerous tariffs on imported goods.
2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now
Buying low to sell later when the stock's price is high is a time-honored investing strategy. With the benchmark S&P 500 index near its all-time high, though, now might seem like the wrong time to go looking for stocks that trade at bargain prices.
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.
Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer: What The Summit Therapeutics Deal Brings
